Scarica l'app Stockscreener
3.07
7.53%
-0.25
Dopo l'orario di chiusura:
3.12
0.05
+1.63%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.32
Aprire:
$3.3
Volume 24 ore:
2.50M
Relative Volume:
0.93
Capitalizzazione di mercato:
$264.67M
Reddito:
$7.62M
Utile/perdita netta:
$-271.60M
Rapporto P/E:
-0.8767
EPS:
-3.5018
Flusso di cassa netto:
$-271.54M
1 W Prestazione:
-3.15%
1M Prestazione:
-27.42%
6M Prestazione:
-78.86%
1 anno Prestazione:
-76.99%
Intervallo 1D:
$3.06
$3.315
Intervallo di 1 settimana:
$3.06
$3.5685
Portata 52W:
$3.05
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Nome
Eyepoint Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
3.07 | 264.67M | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-02 | Downgrade | TD Cowen | Buy → Hold |
| 2026-08-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2026-08-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2026-08-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-08-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-07-16 | Iniziato | Stifel | Buy |
| 2026-07-08 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-06-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-07 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Inc Borsa (EYPT) Ultime notizie
Five parties report an EyePoint (EYPT) stake but disclaim ownership of shares held by Managed Funds. - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - GlobeNewswire Inc.
PV3B Stock Price and Chart — HAN:PV3B - TradingView
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - kalkine.ca
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - kalkine.com.au
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against EyePoint, Inc. (EYPT) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT) - The Globe and Mail
EYPT Investigation Alert: EyePoint, Inc. Investors Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
EyePoint at Cantor conference: mixed trial data leaves key catalyst ahead - Investing.com Canada
EyePoint at Cantor conference: mixed trial data leaves key catalyst ahead - Investing.com India
EyePoint posts updated presentation showing LUGANO Phase 3 DURAVYU topline results, NDA path to H1 2027 - TradingView
Eye drug cuts injections 42% in EyePoint (EYPT) trial but misses its main goal - Stock Titan
EyePoint Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Transcript : EyePoint, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
EyePoint at Citi summit: wet AMD setback, but path stays open - Investing.com India
EyePoint at Citi summit: wet AMD setback, but path stays open - Investing.com Nigeria
EyePoint at Citi summit: wet AMD setback, but path stays open - Investing.com UK
EyePoint at Citi summit: wet AMD setback, but path stays open By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - GlobeNewswire Inc.
INVESTIGATION ALERT: Investigation Launched Into EyePoint, Inc. (EYPT), Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - Barchart.com
Investment firm discloses double-digit stake in EyePoint (EYPT) - Stock Titan
EyePoint's stock plunges 66% after failed Phase 3 trial for wet AMD treatment. - Pluang
Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - PR Newswire
EYPT News | EYEPOINT INC (NASDAQ:EYPT) - ChartMill
EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm - GlobeNewswire Inc.
EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO - finance.yahoo.com
EyePoint faces securities fraud probe after tri... - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - PR Newswire
EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals - GlobeNewswire
EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
EyePoint stock drops as TD Cowen downgrades (EYPT:NASDAQ) - Seeking Alpha
TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20 - marketscreener.com
EyePoint Announces Upcoming Investor Conference and Retina Society Presentations - quiverquant.com
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting - marketscreener.com
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting - GlobeNewswire
TD Cowen downgrades EyePoint stock to Hold on trial concerns By Investing.com - Investing.com Canada
TD Cowen downgrades EyePoint stock to Hold on trial concerns - investing.com
TD Cowen downgrades EyePoint stock to Hold on trial concerns By Investing.com - Investing.com UK
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm - Sahm
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law - financialcontent.com
Eyepoint Pharmaceuticals Inc (EYPT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law - Business Wire
Eyepoint Pharmaceuticals Inc (EYPT) Peer Comparison – Compare with Others - Value Research
EyePoint After LUGANO: Primary Endpoint Miss, Asymmetric Risk-Reward (NASDAQ:EYPT) - Seeking Alpha
EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - FinancialContent
Eyepoint Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Eyepoint Inc Azioni (EYPT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lurker Nancy | Officer |
Jul 21 '26 |
Proposed Sale |
13.05 |
421,235 |
5,497,117 |
0 |
| Duker Jay S. | President and CEO |
Jul 10 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
17,653 |
| Ribeiro Ramiro | Chief Medical Officer |
Jun 30 '26 |
Option Exercise |
8.26 |
4,875 |
40,268 |
4,875 |
| Ribeiro Ramiro | Chief Medical Officer |
Jun 30 '26 |
Sale |
15.01 |
4,875 |
73,167 |
0 |
| Elston George | Chief Financial Officer |
May 25 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
95,318 |
| Ribeiro Ramiro | Chief Medical Officer |
Apr 17 '26 |
Option Exercise |
8.26 |
2,437 |
20,130 |
2,437 |
| Ribeiro Ramiro | Chief Medical Officer |
Apr 17 '26 |
Sale |
15.00 |
2,437 |
36,555 |
0 |
| Ramiro Ribeiro | Officer |
Apr 17 '26 |
Proposed Sale |
14.81 |
9,750 |
144,398 |
0 |
| Duker Jay S. | President and CEO |
Mar 16 '26 |
Buy |
13.15 |
1,500 |
19,724 |
100,665 |
| Ribeiro Ramiro | Chief Medical Officer |
Mar 04 '26 |
Option Exercise |
8.26 |
2,438 |
20,138 |
2,438 |
4.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):